Venous thrombosis
Conditions
Interventions
Low-molecular-weight heparin followed by rivaroxaban:During the hospitalization, standardized heparin treatment was administered. After discharge, rivaroxaban 10 mg was taken orally once daily. The tr
The low-molecular-weight heparin followed by aspirin group:During the hospitalization, standardized heparin treatment was given. After discharge, aspirin 100 mg was taken orally once a day. Treatment
Sponsors
The Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age>= 18 years, planned for THA or TKA; (2) Preoperatively, assessed by Caprini score as having a high VTE risk (>= 8 points); (3) Expected to be able to take oral medications after surgery and complete at least 90-day follow-up; (4) The subject voluntarily participates in the study and signs a written informed consent form.
Exclusion criteria
Exclusion criteria: (1) Active bleeding or high-risk bleeding status; (2) Abnormal coagulation function (such as platelet count 5 times the upper limit of normal value); (4) Severe renal insufficiency (estimated glomerular filtration rate < 30 mL/min, or in a state of kidney transplantation/hemodialysis); (5) Pregnancy or lactation period; (6) Allergic to the study drug (rivaroxaban/aspirin) or having clear contraindications (such as active gastrointestinal ulcer, etc.); (7) Expected survival period < 1 year; (8) Active tumor requiring systemic treatment or recent chemotherapy/radiotherapy; (9) Presence of serious neurological diseases that are unsuitable for surgery or unable to complete follow-up; (10) History of hip/leg fracture within the past 3 months; (11) Recent major surgery within the past 3 months; (12) Long-term anticoagulant therapy due to other comorbidities; (13) Concurrent use of drugs that strongly inhibit or induce P-gp and CYP3A4; (14) Concurrent participation in other interventional clinical trials; (15) Members of the research team or their immediate family members.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptomatic deep vein thrombosis;Symptomatic pulmonary embolism;Bleeding incident; | — |
Secondary
| Measure | Time frame |
|---|---|
| all-cause mortality;Unplanned readmission;Surgical-related complications;Arterial embolism event;Drug-related adverse reactions; | — |
Countries
China
Contacts
Public ContactQiming Liu
The Second Xiangya Hospital of Central South University
Outcome results
None listed